Status:
UNKNOWN
1,3,7-Trimethylxanthine as a Treatment of COVID-19: Results of a Controlled Study
Lead Sponsor:
Poitiers University Hospital
Conditions:
Coronavirus Disease 2019
Eligibility:
All Genders
18-100 years
Brief Summary
This is observational study to assess the prognosis of patients hospitalized with COVID-19 confirmed by RT-PCR and exposed to trimethylxanthine (TMX). Trimethylxanthine is the active molecule present...
Eligibility Criteria
Inclusion
- Age \> 18,
- No Trimethylxanthine contraindications (defined as allergy, previous reported secondary effects),
- Infectious Disease Unit admission.
Exclusion
- Secondary effects about Trimethylxanthine,
- Refuse to participate
Key Trial Info
Start Date :
May 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
93 Patients enrolled
Trial Details
Trial ID
NCT04395742
Start Date
May 1 2020
End Date
December 1 2020
Last Update
May 20 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.